Anti alfa-3 and alfa-7 ganglionic cholinergic receptors antibodies (anti-AChRAbs)
plasma removal acutely improved dysautonomia symptoms in case reports of Pure Autonomic
Failure (PAF). It is unknown whether a long lasting treatment based on repetitive
anti-AChRAbs removal and combined immunosuppressive therapy might durably improve
both cardiovascular autonomic functioning and clinical features. A 50-years-old male
affected by PAF with anti-AChRAbs was studied before anti-AChRAbs removal (Baseline)
and one (T1), two (T2) and three (T3) years from Baseline. Based on the worsening
of symptoms the patient underwent 17 immunoabsorption procedures over the 36 months. Prednisone was administered starting with 50 mg/day and progressively reduced up to 5 mg/die since T2. We evaluated the time course of plasma anti-AChRAbs, the corresponding
changes produced by a gravitational stimulus (75° head-up tilt) in heart rate (ΔHR),
systolic arterial pressure (ΔSAP), spectral indices of cardiac (ΔLF/HF) and vascular
(ΔLFSAP) sympathetic control and plasma norepinephrine (ΔNE). Twelve dysautonomia symptoms
were quantified by a visual analogue scale (VAS, score:0 = no-symptom; 10 = highest-intensity) and averaged (total VAS).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Autonomic Neuroscience: Basic and ClinicalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2015 Published by Elsevier Inc.
